Protocol Ledger

NCT05051891 · Phase III · COMPLETED

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїv

Interventional Phase III clinical trial protocol NCT05051891 sponsored by Beijing InnoCare Pharma Tech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-22 Enrollment: 3 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05051891
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05051891
Protocol FieldVerified Registry Value
NCT IdentifierNCT05051891
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment3 participants (ACTUAL)
Registered Start Date2021-12-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI